RIVAROXABAN TARO 10 MG

Maa: Israel

Kieli: englanti

Lähde: Ministry of Health

Aktiivinen ainesosa:

RIVAROXABAN

Saatavilla:

TARO PHARMACEUTICAL INDUSTRIES LTD

ATC-koodi:

B01AX06

Lääkemuoto:

FILM COATED TABLETS

Koostumus:

RIVAROXABAN 10 MG

Antoreitti:

PER OS

Prescription tyyppi:

Required

Valmistaja:

TARO PHARMACEUTICAL INDUSTRIES LTD

Terapeuttinen alue:

RIVAROXABAN

Käyttöaiheet:

* Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.* Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), in adults (following completion of at least 6 months therapy for DVT or PE).

Valtuutus päivämäärä:

2019-08-06

Pakkausseloste

_Page 1 of 8 _
Patient leaflet in accordance with the Pharmacists’ Regulations
(Preparations) -
1986
This medicine is dispensed with a doctor's prescription only
Rivaroxaban Taro 10 mg
Film-coated tablets
Active ingredient
Each tablet contains:
rivaroxaban 10 mg
Inactive ingredients and allergens in the medicine: see section 2
under ‘Important
information about some of this medicine’s ingredients’, and
section 6 ‘Additional
information'.
Read the entire leaflet carefully before you start using this
medicine. This leaflet
contains concise information about this medicine. If you have any
further questions,
consult your doctor or pharmacist.
This medicine has been prescribed to treat your illness. Do not pass
it on to others. It
may harm them, even if it seems to you that their illness is similar
to yours.
In addition to the leaflet, Rivaroxaban Taro also has a patient safety
information
card. This card contains important safety information that you need to
know and that
you should follow before you start and during treatment with
Rivaroxaban Taro.
Carefully read the patient safety information card and patient
information leaflet
before using this medicine.
Keep the card and the leaflet in case you need to read it again.
1.
What is this medicine intended for?
Rivaroxaban Taro 10 mg is intended for:
•
Prevention of the development of blood clots in the veins in adults
after an elective
hip or knee replacement operation.
•
Prevention of re-ocurrence of blood clots in leg veins (deep vein
thrombosis, DVT)
and in the blood vessels of the lungs (pulmonary embolism, PE), after
completing
6 months of treatment for deep vein thrombosis or previous pulmonary
embolism.
Therapeutic
group:
rivaroxaban
belongs
to
a
group
of
medicines
called
antithrombotic agents and works by blocking a blood clotting factor
(factor Xa) and
thus reducing the tendency of the blood to form clots.
2.
Before using this medicine
Do not use this medicine if:
_Page 2 of 8 _
•
you are sensitive (allergic) to rivaroxaban or to any of the o